GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Gross-Profit-to-Asset %

ANI Pharmaceuticals (FRA:BSFA) Gross-Profit-to-Asset % : 30.49% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ANI Pharmaceuticals's annualized Gross Profit for the quarter that ended in Sep. 2024 was €307.3 Mil. ANI Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2024 was €1,007.7 Mil. Therefore, ANI Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 30.49%.


ANI Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for ANI Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Gross-Profit-to-Asset % Chart

ANI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.69 25.24 19.26 23.94 36.20

ANI Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.58 34.51 38.89 35.19 30.49

Competitive Comparison of ANI Pharmaceuticals's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Gross-Profit-to-Asset % falls into.



ANI Pharmaceuticals Gross-Profit-to-Asset % Calculation

ANI Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=279.963/( (717.522+829.355)/ 2 )
=279.963/773.4385
=36.20 %

ANI Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=307.268/( (855.38+1159.927)/ 2 )
=307.268/1007.6535
=30.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


ANI Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines